It has also been investigated in stroke patients, where administration of recombinant human IL-1Ra (anakinra) was associated with reductions in white blood cell counts, C-reactive protein (CRP), and IL-6 levels, as well as improved functional outcomes at three months in patients with cortical infarcts. This evidence concerns the gene CRP and stroke disorder.